Media Coverage

GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said.

CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the “cytokine storm,” a condition triggered by COVID-19, influenza, and other respiratory viruses. Often,…